ScreenerHero

ATH Alterity Therapeutics Limited

ASX · AU · Healthcare · Biotechnology · alteritytherapeutics.com
—Mkt Cap: —P/E: —

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value21.15M USD
Revenue (TTM)2.49M USD
Gross Profit2.31M USD
Net Income (TTM)-16.17M USD
Revenue/Share0.02 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees11
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000043945
Valuation
P/E (Trailing)—
P/E (Forward)-0.28
PEG1.29
EV/EBITDA-1.22
EV/Revenue8.48
P/S18.76
P/B1.58
EPS (TTM)-0.11
EPS (Forward)-1.10
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin92.72%
Oper. Margin-1816.16%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.77%
ROA-50.85%
Growth
Revenue Growth-79.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.57M USD
CapEx (TTM)—
FCF Margin-408.32%
FCF Yield—
Net Debt-25.66M USD
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity0.00
Current Ratio14.52
Quick Ratio14.26
Book Value/Sh0.20 AUD
Cash/Share0.17 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateJun 3, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.517 AUD
Target Range0.9500 AUD – 10.00 AUD
# Analysts3
Ownership
Shares Out.218.50M
Float173.12M
Insiders8.69%
Institutions17.98%
Technical
SMA 500.4547 AUD
SMA 2000.4681 AUD
Beta-0.01
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)612.18K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—